These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19092439)

  • 1. Abacavir hypersensitivity: a model system for pharmacogenetic test adoption.
    Lai-Goldman M; Faruki H
    Genet Med; 2008 Dec; 10(12):874-8. PubMed ID: 19092439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir pharmacogenetics--from initial reports to standard of care.
    Martin MA; Kroetz DL
    Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prospective validation of a pharmacogenetic test: the PREDICT-1 study].
    Muñoz de Benito RM; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():40-4. PubMed ID: 18680695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
    Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
    Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The frequency of HLA-B(∗)57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.
    Arrieta-Bolaños E; Madrigal JA; Marsh SG; Shaw BE; Salazar-Sánchez L
    Hum Immunol; 2014 Nov; 75(11):1092-6. PubMed ID: 25286002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of drug hypersensitivity.
    Phillips EJ; Mallal SA
    Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir hypersensitivity reaction: an update.
    Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
    Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful translation of pharmacogenetics into the clinic: the abacavir example.
    Phillips E; Mallal S
    Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity.
    Schnyder B; Adam J; Rauch A; Thurnheer MC; Pichler WJ
    J Allergy Clin Immunol; 2013 Sep; 132(3):756-758. PubMed ID: 23706613
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
    Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
    Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].
    Arnedo Valero M
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():34-9. PubMed ID: 18680694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions.
    Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774
    [No Abstract]   [Full Text] [Related]  

  • 16. Abacavir hypersensitivity reaction.
    AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
    [No Abstract]   [Full Text] [Related]  

  • 17. Current trends in screening across ethnicities for hypersensitivity to abacavir.
    Rodriguez-Nóvoa S; Soriano V
    Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
    Munderi P; Snowden WB; Walker AS; Kityo C; Mosteller M; Kabuye G; Thoofer NK; Ssali F; Gilks CF; Hughes AR;
    Trop Med Int Health; 2011 Feb; 16(2):200-4. PubMed ID: 21091860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
    Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.
    Hughes DA; Vilar FJ; Ward CC; Alfirevic A; Park BK; Pirmohamed M
    Pharmacogenetics; 2004 Jun; 14(6):335-42. PubMed ID: 15247625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.